Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8820853 | 0.75 | AURKA (0.34) | MAPK14 | |
| SCHEMBL28103741 | 0.75 | GRM4 (0.36) | MAPK14 | |
| SCHEMBL2619212 | 0.75 | PIM1 (0.34) | PIM1MAPK14 | |
| SCHEMBL16652137 | 0.73 | GSK3B (0.37) | MAPK1PIM1 | |
| SCHEMBL11947207 | 0.71 | DGAT1 (0.30) | — | |
| SCHEMBL4325438 | 0.71 | CCNT1 (0.40) | CCNT1CDK9HASPIN | |
| SCHEMBL13153053 | 0.71 | HTR6 (0.31) | — | |
| SCHEMBL2611062 | 0.71 | FFAR1 (0.30) | — | |
| SCHEMBL13725532 | 0.71 | CCNT1 (0.40) | CCNT1CDK9HASPIN | |
| Hydrochloric Acid SCHEMBL5047877 | 0.69 | CCNT1 (0.39) | CCNT1CDK9HASPIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025119184-A1 | SUBSTITUTED POLYCYCLIC COMPOUND | 首药控股(北京)股份有限公司 | 2025-06-12 | — | — | WO | disclosed |
| WO-2021083438-A1 | INHIBITORS OF PURINE NUCLEOSIDE PHOSPHORYLASE - SYNTHESIS AND USE THEREOF FOR TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOMA | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V. V. I. (CZ) | 2021-05-06 | — | — | WO | disclosed |
| CN-103958510-B | For treating the Pyrrolopyrimidine compounds of cancer | 北卡罗来纳大学教堂山分校 | 2016-10-19 | — | — | CN | disclosed |
| CN-103958510-A | Pyrrolopyrimidine compounds for the treatment of cancer | UNIV NORTH CAROLINA | 2014-07-30 | — | — | CN | disclosed |
| CN-101062928-B | Process for preparing 2-pyrrolidinyl-1h-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside metabolism | IND RES LTD | 2010-10-06 | — | — | CN | disclosed |
| EP-2077268-A1 | Process for preparing inhibitors of nucleoside metabolism | Industrial Research Limited (NZ) | 2009-07-08 | — | — | EP | disclosed |
| EP-1165564-B1 | PROCESS FOR PREPARING INHIBITORS OF NUCLEOSIDE METABOLISM | IND RES LTD (NZ) | 2009-03-11 | — | — | EP | disclosed |
| US-7405297-B2 | Process for preparing inhibitors of nucleoside metabolism | INDUSTRIAL RESEARCH LIMITED (NZ) | 2008-07-29 | — | — | US | disclosed |
| CN-101062928-A | Process for preparing 2-pyrrolidinyl-1h-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside metabolism | IND RES LTD (NZ) | 2007-10-31 | — | — | CN | disclosed |
| CN-100344630-C | 3H, 5H-pyrrolo [3, 2-d ] pyrimidin-4-one derivatives and process for producing the same | IND RES LTD (NZ) | 2007-10-24 | — | — | CN | disclosed |
| US-20060089498-A1 | Process for preparing inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2006-04-27 | — | — | US | disclosed |
| US-7022852-B2 | Process for preparing inhibitors of nucleoside metabolism | INDUSTRIAL RESEARCH LIMITED (NZ) | 2006-04-04 | — | — | US | disclosed |
| CN-1727341-A | 3H, 5H-pyrrolo [3, 2-d ] pyrimidin-4-one derivatives and process for producing the same | IND RES LTD (NZ) | 2006-02-01 | — | — | CN | disclosed |
| CN-1196704-C | Process for preparing nucleoside metabolism inhibitor and intermediate compound | IND RES LTD (NZ) | 2005-04-13 | — | — | CN | disclosed |
| US-20040181063-A1 | Process for preparing inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2004-09-16 | — | — | US | disclosed |
| US-6693193-B1 | COUPLING AN N- AND O-PROTECTED 2,3-DIHYDROXY-PYRROLIDINE TO THE 2-POSITION AND DEPROTECTING | INDUSTRIAL RESEARCH LIMITED (NZ) | 2004-02-17 | — | — | US | disclosed |
| EP-1165564-A4 | PROCESS FOR PREPARING INHIBITORS OF NUCLEOSIDE METABOLISM | IND RES LTD (NZ) | 2003-01-22 | — | — | EP | disclosed |
| CN-1370171-A | Process for preparing nucleoside metabolism inhibitors | IND RES LTD (NZ) | 2002-09-18 | — | — | CN | disclosed |
| EP-1165564-A2 | PROCESS FOR PREPARING INHIBITORS OF NUCLEOSIDE METABOLISM | INDUSTRIAL RESEARCH LIMITED (NZ) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000061783-A2 | PROCESS FOR PREPARING INHIBITORS OF NUCLEOSIDE METABOLISM | INDUSTRIAL RESEARCH LIMITED (NZ) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089498-A1 | Process for preparing inhibitors of nucleoside metabolism | UGT1A3, AGL, PNP | MAPK1 2046/4885CCNT1 879/4885PIM1 4647/4885 |
| US-20040181063-A1 | Process for preparing inhibitors of nucleoside metabolism | XDH, PNP, AGL | MAPK1 1320/4885CCNT1 715/4885PIM1 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.